PPID study finds same lifespan, but more medical events in horses
A new study is sharpening the clinical picture of pituitary pars intermedia dysfunction in horses: PPID doesn’t appear to shorten life expectancy, but it does seem to increase the medical burden horses carry as they age. The paper, recently indexed in PubMed and covered by The Horse, found that horses diagnosed with PPID experienced more medical events during their lifetime than matched horses without the diagnosis. (pubmed.ncbi.nlm.nih.gov)
That distinction matters because PPID has long been associated with advanced age, chronic management needs, and serious complications such as laminitis. In the AVMA Veterinary Vertex podcast episode on the study, the authors said they initially expected PPID horses in first-opinion practice to die earlier than controls. Instead, what stood out was not reduced survival, but the broader pattern of comorbidity and care needs. The podcast also underscored a practical challenge familiar to equine clinicians: horses can test negative earlier in life and later develop PPID or insulin dysregulation, so a single normal result shouldn’t be treated as permanent reassurance. (veterinaryvertex.buzzsprout.com)
The study’s key associations were clinically relevant ones. According to the PubMed summary, factors independently associated with a PPID diagnosis included poor healing, dental issues, including missing teeth or equine odontoclastic tooth resorption and hypercementosis, hyperinsulinemia-associated laminitis, and NSAID prescribing. Those findings align with the broader understanding of PPID as a disease that intersects with endocrine dysfunction, pain management, hoof health, and the complexities of geriatric equine care. (pubmed.ncbi.nlm.nih.gov)
Outside this study, the current guidance landscape points in the same direction. The 2023 Equine Endocrinology Group recommendations state that medical management of PPID improves quality of life but does not necessarily prolong lifespan. They also note that ACTH concentrations can begin rising within 48 hours if pergolide doses are missed, reinforcing how dependent many cases are on consistent long-term management. Meanwhile, BEVA’s primary care guidelines say there is little advantage in waiting more than a month for follow-up endocrine testing after starting pergolide, though the evidence base for exactly how best to monitor and titrate therapy remains limited. (idppid.com)
Longer-term treatment data add more context. A separate long-term pergolide study found sustained owner-reported clinical improvement over years of treatment, but its authors were careful not to claim a survival benefit because untreated controls were not followed in parallel. That study reported a median survival time of 3.6 years after enrollment, while emphasizing improved quality of life rather than longer life. Taken together with the new PPID lifespan paper, the emerging message is consistent: treatment may help horses live better, even if it doesn’t clearly help them live longer. (pmc.ncbi.nlm.nih.gov)
Why it matters: For veterinary professionals, this shifts the clinical conversation from a narrow prognosis question to a chronic-care framework. A PPID diagnosis should prompt repeated screening for insulin dysregulation and laminitis risk, attention to dental disease and wound healing, medication review, and realistic counseling for pet parents about what success looks like. Success may be fewer complications, better comfort, and preserved function, rather than added years. That’s especially important in older horses, where PPID often overlaps with other age-related disease processes and where quality-of-life decisions can become more complex over time. (cvm.msu.edu)
What to watch: The next step for the field is likely more work on monitoring strategies and risk stratification in primary care, including which horses need closer surveillance for laminitis, dental pathology, or worsening endocrine control, and whether earlier detection changes the long-term burden of disease. (pubmed.ncbi.nlm.nih.gov)